Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | 2025-10-16 17:01:02 | 2.44 | 0.04 | 1.67 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | 0001006281 | Protalix BioTherapeutics, Inc. | US74365A3095 | 549300SDVB3GP4XDFM60 | 650643773 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 2 UNIVERSITY PLAZA | HACKENSACK | NJ | 07601 | UNITED STATES | US | 201-696-9345 | 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601 | 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601 | ORTHODONTIX INC | Biotechnology | 1993 | Moshe Manor | 266 | http://protalix.com | 82,000,000 | 75,850,275 | 79,732,115 | Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. | 2025-10-10 22:34:01 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 82,000,000 | -57,300,000 | -41.1342 | 78,032,585 | 4,980,461 | 6.8177 |
| 2023 | 139,300,000 | 87,100,000 | 166.8582 | 73,052,124 | 7,637,207 | 11.675 |
| 2022 | 52,200,000 | -32,900,000 | -38.6604 | 65,414,917 | 19,098,788 | 41.2357 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Yaron Naos | Senior Vice President | 2024 | 215,546 | 95,083 | 166,353 | — | 85,842 | 639,959 |
| Eyal Rubin | Chief Financial Officer, Senior Vice President | 2024 | 287,363 | 130,399 | 288,669 | — | 97,594 | 859,466 |
| Dror Bashan | Chief Executive Officer, President | 2024 | 374,108 | 0 | 918,318 | — | 116,563 | 1,527,792 |
| Eyal Rubin | Chief Financial Officer, Senior Vice President | 2023 | 287,692 | 302,507 | 227,331 | — | 96,580 | 1,029,035 |
| Dror Bashan | Chief Executive Officer, President | 2023 | 356,929 | 892,328 | 1,061,558 | — | 127,566 | 2,684,941 |
| Fiscal Year | Employee Count |
|---|---|
| 2022 | 197 |
| 2021 | 206 |
| 2020 | 207 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 53,399,000 | 65,494,000 | 47,638,000 |
| Cost Of Revenue | 24,319,000 | 22,982,000 | 19,592,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 12,970,000 | 17,093,000 | 29,349,000 |
| General And Administrative Expenses | 12,193,000 | 14,959,000 | 11,711,000 |
| Operating Expenses | — | — | — |
| Operating Income | 3,917,000 | 10,460,000 | -13,014,000 |
| Net Income | 2,932,000 | 8,312,000 | -14,927,000 |
| Earnings Per Share Basic | 0.04 | 0.12 | -0.31 |
| Earnings Per Share Diluted | 0.04 | 0.09 | -0.31 |
| Weighted Average Shares Outstanding Basic | 72,530,698 | 67,512,527 | 48,472,159 |
| Weighted Average Shares Outstanding Diluted | 81,057,176 | 82,424,016 | 48,472,159 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 19,760,000 | 23,634,000 | 17,111,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 2,909,000 | 5,272,000 | 4,586,000 |
| Inventories | 21,243,000 | 19,045,000 | 16,804,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,096,000 | 1,055,000 | 1,310,000 |
| Total Assets Current | 60,078,000 | 69,932,000 | 44,880,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,591,000 | 4,973,000 | 4,553,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 13,339,000 | 14,502,000 | 10,907,000 |
| Total Assets | 73,417,000 | 84,434,000 | 55,787,000 |
| Accounts Payable | 4,533,000 | 19,550,000 | 12,271,000 |
| Deferred Revenue | — | 0 | 13,178,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 9,568,000 | 9,009,000 | 8,008,000 |
| Total Liabilities Current | 25,621,000 | 45,530,000 | 32,429,000 |
| Long Term Debt | — | — | 28,187,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 4,585,000 | 5,335,000 | 33,998,000 |
| Total Liabilities | 30,206,000 | 50,865,000 | 66,427,000 |
| Common Stock | 76,000 | 73,000 | 54,000 |
| Retained Earnings | -378,393,000 | -381,549,000 | -389,861,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 43,211,000 | 33,569,000 | -10,640,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,304,000 | 1,191,000 | 1,086,000 |
| Share Based Compensation Expense | 3,253,000 | 3,448,000 | 2,085,000 |
| Other Non Cash Income Expense | 3,000 | -9,000 | 0 |
| Change In Accounts Receivable | -2,317,000 | 428,000 | 1,194,000 |
| Change In Inventories | 2,198,000 | 2,241,000 | -1,150,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 696,000 | 5,295,000 | -4,804,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 8,674,000 | -1,318,000 | -25,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,282,000 | 1,149,000 | 628,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -80,000 | 142,000 | -593,000 |
| Cash From Investing Activities | 4,221,000 | -16,711,000 | -5,035,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 3,626,000 | 23,954,000 | 8,236,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -16,794,000 | 24,666,000 | 8,238,000 |
| Change In Cash | -3,874,000 | 6,523,000 | -21,874,000 |
| Cash At End Of Period | 19,760,000 | 23,634,000 | 17,111,000 |
| Income Taxes Paid | 385,000 | — | — |
| Interest Paid | 1,532,000 | 2,742,000 | 2,198,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.04 | 0.12 | -0.31 |
| Price To Earnings Ratio | 47 | 14.8333 | -4.4194 |
| Earnings Growth Rate | -66.6667 | -138.7097 | -50 |
| Price Earnings To Growth Ratio | -0.705 | -0.1069 | 0.0884 |
| Book Value Per Share | 0.5958 | 0.4972 | -0.2195 |
| Price To Book Ratio | 3.1556 | 3.5799 | -6.2412 |
| Ebitda | 5,643,000 | 12,304,000 | -11,385,000 |
| Enterprise Value | — | — | 77,482,857.83 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | -2.6492 |
| Capital Expenditures | 922,000 | 1,611,000 | 677,000 |
| Free Cash Flow | 7,752,000 | -2,929,000 | -25,677,000 |
| Return On Equity | 0.0679 | 0.2476 | 1.4029 |
| One Year Beta | 0.6057 | 0.2489 | 0.5782 |
| Three Year Beta | 0.5124 | 0.662 | 0.683 |
| Five Year Beta | 0.6466 | 0.6262 | 0.6537 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Bashan Dror | Director, PRESIDENT AND CEO | 2025-09-03 | 195,000 | A | 2,344,418 |
| Bashan Dror | Director, PRESIDENT AND CEO | 2025-09-03 | 340,000 | A | 340,000 |
| Naos Yaron | Sr. VP, Operations | 2025-09-03 | 25,000 | A | 225,817 |
| Naos Yaron | Sr. VP, Operations | 2025-09-03 | 50,000 | A | 50,000 |
| Bar-Shalev Amos | Director | 2025-09-03 | 7,500 | A | 7,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| NEW YORK STATE COMMON RETIREMENT FUND | 2025-06-30 | 102,120 | 69,000 | 1.48 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 1,036 | 700 | 1.48 |
| WOLVERINE TRADING, LLC | 2025-06-30 | 32,032 | 20,800 | 1.54 |
| WOLVERINE TRADING, LLC | 2025-06-30 | 37,742 | 24,508 | 1.54 |
| MORGAN STANLEY | 2025-06-30 | 683,823 | 462,043 | 1.48 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 35,246 | 51,459.16 | 0.0039 |
| ProFunds | 2025-07-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 63 | 91.98 | 0.0026 |
| ProFunds | 2025-07-31 | SMALL-CAP PROFUND INVESTOR CLASS | SLPIX | 63 | 91.98 | 0.0026 |
| ProFunds | 2025-07-31 | ULTRASMALL-CAP PROFUND SERVICE CLASS | UAPSX | 772 | 1,127.12 | 0.0028 |
| ProFunds | 2025-07-31 | ULTRASMALL-CAP PROFUND INVESTOR CLASS | UAPIX | 772 | 1,127.12 | 0.0028 |